Trial Profile

Phase I/IIa Study of Intratumoral/Intracerebral or Intravenous/Intracerebral Administration of Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Nov 2019 According to an Oryx GmbH & Co media release, the company received a positive feedback and endorsement from both agencies to evaluate its proposed plans for pivotal studies.
04 Nov 2019 According to an Oryx GmbH & Co media release, based on the data from this trial and the follow-up program the company requested meetings with the regulatory authorities both in the EU and US to discuss pivotal studies with ParvOryx in combination with bevacizumab for the treatment of recurrent glioblastoma multiforme (rGBM).
16 May 2018 Results presented in the GmbH & Co media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com